Understanding epilepsy
Epilepsy is one of the most common neurological conditions, affecting roughly 1 in 100 people in the UK. It causes recurrent seizures, which are sudden bursts of abnormal electrical activity in the brain. Seizures can range from brief lapses in awareness to full convulsions, and their impact on daily life can be significant.
For about two thirds of people with epilepsy, anti-seizure medications provide effective control. That still leaves around a third who continue to experience seizures despite trying multiple medications. Neurologists describe this as drug-resistant epilepsy.
Medications can also come with unwelcome side effects. Fatigue, cognitive difficulties, mood changes, and weight gain are common complaints. For many people, the combined burden of ongoing seizures and medication side effects takes a real toll on quality of life, relationships, and independence.
This is why there is a genuine need for additional approaches that can work alongside medication to improve seizure control.
How tVNS helps
Transcutaneous vagus nerve stimulation (tVNS) is a non-invasive way to stimulate the vagus nerve through the skin of the ear. A small clip-style electrode attaches to the outer ear, targeting a branch of the vagus nerve called the auricular branch. This is the only place where the vagus nerve comes close enough to the surface of the skin to be reached without surgery.
The device delivers gentle electrical pulses through this electrode. You might feel a mild tingling or buzzing sensation, but it should never be painful. These electrical signals travel along the vagus nerve to the brainstem, specifically to an area called the nucleus tractus solitarius. From there, the signals influence brain networks that are involved in seizure activity.
The concept builds on decades of experience with implanted vagus nerve stimulators (VNS), which have been used for drug-resistant epilepsy since 1997. Implanted VNS requires surgery to place an electrode around the vagus nerve in the neck and a pulse generator under the skin of the chest. tVNS offers a non-surgical route to similar benefits, with the advantage that you can use it at home without an operation.
The evidence
The evidence for tVNS in epilepsy draws on the strong foundation established by implanted VNS research, combined with a growing body of studies on the transcutaneous approach.
In long-term studies spanning five years, tVNS provides a responder rate (the proportion of people achieving at least a 50% reduction in seizure frequency) of around 30%. This is comparable to the 32% responder rate seen with implanted VNS over the same timeframe. The fact that a non-invasive approach can match the outcomes of a surgical implant is clinically meaningful.
A pilot trial using the NEMOS device, one of the established tVNS systems, demonstrated a 34.2% reduction in seizure frequency over a 20-week treatment period. While pilot studies are smaller in scale, this result is encouraging and consistent with the broader evidence.
It is worth being straightforward about what these numbers mean. A 30% responder rate tells us that roughly one in three people will see a meaningful improvement. That also means two in three may not respond as strongly. Outcomes vary between individuals, and there is currently no reliable way to predict who will benefit most. The research continues to develop.
What treatment looks like
tVNS is designed for daily home use, making it a practical addition to your existing management plan. The device clips onto the outer ear, and a typical treatment session lasts between one and four hours per day. Many people build it into their routine while reading, watching television, or resting.
Your clinician will set the stimulation parameters, including the intensity, pulse width, and frequency. These are tailored to you and adjusted over time based on your response. A companion app allows you to track your sessions and seizure activity, which gives both you and your clinical team useful data for managing your treatment.
It is important to understand that tVNS is not a replacement for your current medication. It works as part of a broader management plan, alongside your existing treatments and under the guidance of your neurologist or specialist. The goal is to provide an additional tool that may improve your overall seizure control and quality of life.
Is this right for me?
Whether tVNS is appropriate for you depends on your individual circumstances, and that assessment needs to be made with a qualified clinician.
tVNS may be worth considering if you have drug-resistant epilepsy, particularly partial-onset seizures, and you are looking for a non-surgical option that can complement your current treatment. It is also an option if you have considered implanted VNS but prefer to try a non-invasive approach first.
Not everyone is suitable for tVNS. There are contraindications that your clinician will check for, including implanted cardiac devices such as pacemakers or defibrillators, and certain other medical conditions. A thorough clinical assessment is always the first step.
It is also honest to say that response to tVNS varies. Some people experience a significant reduction in seizure frequency, while others see more modest improvements or may not respond. A lot depends on individual factors that we do not yet fully understand. What the evidence does tell us is that for those who do respond, tVNS can make a meaningful difference to daily life.
Next steps
If you would like to find out whether tVNS could be part of your epilepsy management, we are here to help. Contact us to arrange a clinical assessment where we can discuss your situation, answer your questions, and help you make an informed decision about whether this approach is right for you.